Concomitant Cisplatin Plus Radiotherapy and High-Dose-Rate Brachytherapy Versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Randomized Controlled Trial

dc.creatorZuliani, AC
dc.creatorEsteves, SCB
dc.creatorTeixeira, LC
dc.creatorTeixeira, JC
dc.creatorde Souza, GA
dc.creatorSarian, LO
dc.date2014
dc.dateFEB 20
dc.date2014-07-30T14:00:34Z
dc.date2015-11-26T16:33:30Z
dc.date2014-07-30T14:00:34Z
dc.date2015-11-26T16:33:30Z
dc.date.accessioned2018-03-28T23:15:23Z
dc.date.available2018-03-28T23:15:23Z
dc.identifierJournal Of Clinical Oncology. Amer Soc Clinical Oncology, v. 32, n. 6, n. 542, n. 547, 2014.
dc.identifier0732-183X
dc.identifier1527-7755
dc.identifierWOS:000332788900013
dc.identifier10.1200/JCO.2013.50.1205
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/56461
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/56461
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1270872
dc.descriptionPurpose The benefits of chemoradiotherapy (CRT) for cervical cancer compared with radiation (RT) alone seem to diminish in later-stage disease. However, these modalities have not been directly compared for disease-free interval (DFI) and overall survival (OS) of women with stage IIIB cervical cancer. Patients and Methods We conducted a randomized controlled clinical trial comparing DFI and OS of 147 women with stage IIIB squamous cervical cancer who received either cisplatin plus RT (CRT) or RT alone (72 patients in the CRT group and 75 patients in the RT-only group). Results The CRT group had significantly better DFI (hazard ratio [HR], 0.52; 95% CI, 0.29 to 0.93; P = .02). However, patients in the CRT group did not have significantly better OS than those in the RT-only group (HR, 0.67; 95% CI, 0.38 to 1.17; P = .16). Toxicity was graded according to criteria of the Radiation Therapy Oncology Group. The organs affected (excluding hematologic effects) did not differ significantly between groups. Also, late toxicity events and organs affected were not significantly disproportionate between the study groups. Conclusion For stage IIIB cervical cancer, the addition of cisplatin offers a small but significant benefit in DFI, with acceptable toxicity. (C) 2014 by American Society of Clinical Oncology
dc.description32
dc.description6
dc.description542
dc.description547
dc.languageen
dc.publisherAmer Soc Clinical Oncology
dc.publisherAlexandria
dc.publisherEUA
dc.relationJournal Of Clinical Oncology
dc.relationJ. Clin. Oncol.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectRate Intracavitary Brachytherapy
dc.subjectExternal-beam Radiotherapy
dc.subjectRadiation-therapy
dc.subjectConcurrent Chemotherapy
dc.subjectPelvic Radiation
dc.subjectLate Toxicities
dc.subjectOncology-group
dc.subjectCarcinoma
dc.titleConcomitant Cisplatin Plus Radiotherapy and High-Dose-Rate Brachytherapy Versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Randomized Controlled Trial
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución